Royal Bank Of Canada Issues Positive Forecast for Zimmer Biomet (NYSE:ZBH) Stock Price

Key Points

• Royal Bank of Canada raised its Zimmer Biomet price target from $110 to $125 and maintained an “outperform” rating, implying 18.05% upside from the prior close. Overall, analysts’ consensus rating is “Hold,” with an average target of $108.42.
• Zimmer Biomet’s quarterly revenue rose 3.1% to $2.06 billion, and adjusted EPS of $1.90 slightly beat estimates. The company raised its 2026 outlook, though weaker knee sales and a decline in reported diluted EPS reflected ongoing business pressures.
• Shares fell $4.26 to $105.89 in Thursday trading.

Zimmer Biomet (NYSE:ZBH - Get Free Report) had its price objective boosted by stock analysts at Royal Bank Of Canada from $110.00 to $125.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has an "outperform" rating on the medical equipment provider's stock. Royal Bank Of Canada's target price suggests a potential upside of 18.05% from the stock's previous close.

Several other research analysts also recently issued reports on ZBH. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a report on Thursday, August 6th. Jefferies Financial Group reissued a "hold" rating and set a $120.00 price target on shares of Zimmer Biomet in a research report on Wednesday. Canaccord Genuity Group lifted their price objective on shares of Zimmer Biomet from $83.00 to $100.00 and gave the stock a "hold" rating in a research report on Monday, August 10th. Stifel Nicolaus set a $125.00 price target on Zimmer Biomet in a research note on Wednesday. Finally, Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research note on Wednesday, August 5th. Seven investment analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $108.42.

Zimmer Biomet Price Performance

NYSE ZBH traded down $4.26 during trading on Thursday, reaching $105.89. 2,141,047 shares of the company traded hands, compared to its average volume of 2,259,370. Zimmer Biomet has a 1-year low of $79.12 and a 1-year high of $112.54. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. The stock's 50 day moving average price is $94.90 and its two-hundred day moving average price is $91.89. The company has a market cap of $20.20 billion, a price-to-earnings ratio of 25.76, a P/E/G ratio of 2.33 and a beta of 0.50.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 EPS for the quarter, beating the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The business had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2.04 billion. During the same quarter in the previous year, the firm earned $1.90 EPS. Zimmer Biomet's quarterly revenue was up 3.1% on a year-over-year basis. As a group, analysts anticipate that Zimmer Biomet will post 8.54 EPS for the current year.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, insider Chad Phipps sold 3,000 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the transaction, the insider directly owned 65,231 shares of the company's stock, valued at approximately $6,415,468.85. This represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the business's stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $92.95, for a total value of $528,978.45. The disclosure for this sale is available in the SEC filing. Company insiders own 1.28% of the company's stock.

Institutional Investors Weigh In On Zimmer Biomet

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in Zimmer Biomet in the 2nd quarter valued at $1,344,282,000. State Street Corp boosted its stake in Zimmer Biomet by 0.6% during the second quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider's stock worth $766,343,000 after buying an additional 52,044 shares during the last quarter. Primecap Management Co. CA purchased a new stake in Zimmer Biomet in the second quarter valued at $328,578,000. Dimensional Fund Advisors LP boosted its stake in shares of Zimmer Biomet by 1.1% in the first quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider's stock valued at $201,082,000 after purchasing an additional 24,208 shares during the period. Finally, Bank of America Corp DE purchased a new stake in shares of Zimmer Biomet during the 2nd quarter worth approximately $187,480,000. Hedge funds and other institutional investors own 88.89% of the company's stock.

More Zimmer Biomet News

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Third-quarter sales rose 3.1% to $2.063 billion, beating estimates, and adjusted EPS of $1.90 also topped consensus. The company raised its 2026 outlook, with strong hip and sports, extremities and trauma (S.E.T.) sales helping offset a difficult knee market. Zimmer Biomet Q3 results
• Positive Sentiment: Wells Fargo raised its price target to $113 from $103, while keeping an “equal weight” rating. Wells Fargo rating
• Neutral Sentiment: Sanford C. Bernstein lifted its target to $107 from $93 but maintained a “market perform” rating, signaling a more cautious view than a bullish upgrade. Bernstein rating
• Negative Sentiment: Knee sales were a drag, and reported diluted EPS fell 13.8% to $1.00; adjusted EPS was unchanged from a year earlier. These results point to continued product-mix and margin pressures despite the sales beat and improved outlook. Q3 profit and outlook report

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.